Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1261 to 1275 of 1335 results for primary care

  1. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    14 September 2022
    View recommendations

    Sections for TA824

  2. Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)

    Evidence summaries: unlicensed and off-label medicines – Interim process statement

  3. Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]

    In development [GID-TA10933] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]

    Discontinued [GID-TA10315]

    Technology appraisal guidance
    Discontinued

  5. Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]

    Discontinued [GID-TA10324]

    Technology appraisal guidance
    Discontinued

  6. Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)

    Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.

    Technology appraisal guidance
    Published
    6 December 2023
    View recommendations

    Sections for TA935

  7. Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

    Discontinued [GID-TA10295]

    Technology appraisal guidance
    Discontinued

  8. Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)

    Evidence-based recommendations on cipaglucosidase alfa (Pombiliti) with miglustat (Opfolda) for treating late-onset Pompe disease in adults.

    Technology appraisal guidance
    Published
    15 August 2023
    View recommendations

    Sections for TA912

  9. Avelumab for maintenance treatment of advanced gastric or gastro-oesophageal junction cancer after platinum-based chemotherapy [ID2693]

    Discontinued [GID-TA10628]

    Technology appraisal guidance
    Discontinued

  10. Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]

    Discontinued [GID-TA10221]

    Technology appraisal guidance
    Discontinued

  11. Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

    Discontinued [GID-TA10591]

    Technology appraisal guidance
    Discontinued

  12. Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]

    In development [GID-TA10906] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Baricitinib for moderate to severe rheumatoid arthritis (TA466)

    Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    9 August 2017
    View recommendations

    Sections for TA466

  14. Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

    Discontinued [GID-TA10418]

    Technology appraisal guidance
    Discontinued

  15. Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]

    Discontinued [GID-TA10158]

    Technology appraisal guidance
    Discontinued